Sonova Holding (OTCMKTS:SONVY) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Sonova Holding (OTCMKTS:SONVY) have been assigned a consensus recommendation of “Hold” from the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company.

SONVY has been the subject of a number of research reports. Zacks Research lowered Sonova from a “hold” rating to a “strong sell” rating in a research report on Tuesday, December 9th. BNP Paribas began coverage on shares of Sonova in a research report on Monday, October 20th. They issued an “underperform” rating for the company. Rothschild Redb upgraded shares of Sonova from a “strong sell” rating to a “hold” rating in a report on Monday, October 6th. Finally, Royal Bank Of Canada raised shares of Sonova to a “moderate buy” rating in a research report on Tuesday, November 18th.

Sonova Trading Up 0.6%

Shares of Sonova stock opened at $52.94 on Friday. Sonova has a 12 month low of $47.55 and a 12 month high of $71.50. The company has a quick ratio of 0.91, a current ratio of 1.24 and a debt-to-equity ratio of 0.51. The business has a fifty day simple moving average of $51.42 and a 200-day simple moving average of $55.26.

Sonova Company Profile

Sonova AG (OTCMKTS:SONVY) is a Switzerland-based provider of hearing care solutions, headquartered in Stäfa. The company designs, develops, manufactures and distributes a range of audiological products and related services aimed at improving hearing and communication for people with hearing loss. Its portfolio spans behind-the-ear and in-the-ear hearing instruments, wireless accessories and software solutions that enable connectivity with consumer devices and audiological fittings.

Sonova markets its products under several well-known brands, including Phonak and Unitron for hearing aids, and it is also associated with Advanced Bionics for cochlear implant systems.